Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$48.86 USD
+1.51 (3.19%)
Updated Jun 5, 2024 12:54 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 281 - 300 ( 301 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Biotechnology: Panic Has Created Some Compelling Opportunities on the Long Side
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Awaiting Clarity from AG-120 and AG-348 Before Getting Constructive
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Focus Now on the Upcoming EHA Data Deluge
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
IDH Programs Positioned to be the Next Standard-of-Care in IDHm-AML
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Introduction of AG-881 Throws a Curveball,Reiterate Neutral
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Healthcare -Biotechnology: Catalyst Tracker Through Mid-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Healthcare: Biotechnology: Its Yogi Berra All Over Again
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Lull in News Flow Till 2H15, Awaiting Better Entry Points
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
4Q/FY-14 Preview, Upcoming AG-120 Data Key to Support Valuation
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Transformational Science, But Valuation Keeps Us On the Sidelines
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D